Illuminata senior analyst Gordon Haff
thinks Apple's recently announced deal with COLSA gives Apple the credibility to make further inroads in "sci-tech" at lower levels as well. "They are seeing wins in biotech with smaller deals, and this deal legitimizes the PowerPC architecture they are using in their products," Haff told MacNewsWorld.